Drugs / REGN20934
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07594093 | Jun 2026 → Feb 2027 expected | obesity disorder | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN20934 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07594093 ↗ |